FINWIRES · TerminalLIVE
FINWIRES

RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13

By

BioCryst Pharmaceuticals (BCRX) has an average rating of buy and mean price target of $20.64, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120

Revvity (RVTY) has an average rating of overweight and mean price target of $127.29, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$RVTY
Research

UBS Downgrades Mettler-Toledo International to Neutral From Buy, Adjusts Price Target to $1,460 From $1,650

Mettler-Toledo International (MTD) has an average rating of hold and mean price target of $1,472.92, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$MTD
Research

UBS Downgrades Agilent Technologies to Neutral From Buy, $165 Price Target

Agilent Technologies (A) has an average rating of overweight and mean price target of $175.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$A